IP Library Granted Patent US 12,064,537
Granted Patent B2
US 12,064,537 · App. 17/553,509 · Granted Aug 20, 2024

Kits and methods for preparing pathogen-inactivated platelet compositions

Inventors: Tovo David (San Francisco, CA); Betsy Donnelly (Moraga, CA); Anna Erickson (Richmond, CA); Naheed Mufti (Danville, CA)
Assignee: Cerus Corporation
A61M1/0272A61K35/19A61L2/0011A61L2/0029A61L2/0088A61M1/0209A61M1/3496A61M1/3679A61M1/3683A61M2202/0415A61M2202/0427
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,064,537
App. No.
17/553,509
Granted
Aug 20, 2024
Kind
B2
Abstract

Provided are methods for preparing pathogen-inactivated platelet compositions, as well as processing sets and compositions related thereto.

Claims (56)

1. A processing set for preparing a pathogen-inactivated platelet composition, comprising:

(a) a first container that contains a pathogen inactivation compound (PIC) and is suitable for combining a platelet composition with the PIC, wherein the PIC is a psoralen;

(b) a second container, coupled to the first container, within which the platelet composition in admixture with the PIC can be photochemically inactivated, wherein the platelet composition has a volume of about 250 mL to about 750 mL; and

(c) a third container containing a compound adsorption device (CAD), wherein the third container is coupled to the second container such that the photochemically inactivated platelet composition can be transferred from the second container to the third container under sterile conditions;

wherein at least one of (i) and (ii) applies:

(i) the volume of the third container is about 1.2 L to about 1.6 L; and

(ii) the surface area of the interior of the third container is about 800 cm 2 to about 1200 cm 2 .

2. The processing set of claim 1 , further comprising one or more fourth containers, wherein the one or more fourth containers are coupled to the third container such that the photochemically inactivated platelet composition can be transferred from the third container to the one or more fourth containers under sterile conditions to provide the pathogen-inactivated platelet composition.

3. The processing set of claim 2 , comprising two fourth containers.

4. The processing set of claim 2 , comprising three fourth containers.

5. The processing set of claim 1 , wherein the volume of the third container is about 1.2 L to about 1.6 L.

6. The processing set of claim 1 , wherein the volume of the third container is about 1.3 L.

7. The processing set of claim 1 , wherein the surface area of the interior of the third container is about 800 cm 2 to about 1200 cm 2 .

8. The processing set of claim 1 , wherein the surface area of the interior of the container containing the CAD is about 850 cm 2 to about 1100 cm 2 .

9. The processing set of claim 1 , wherein the platelet composition comprises at least about 6.0×10 11 platelets.

10. The processing set of claim 1 , wherein the platelet composition comprises about 6.0×10 11 to about 12.0×10 11 platelets.

11. The processing set of claim 1 , wherein the platelet composition has a volume of about 300 mL to about 650 mL.

12. The processing set of claim 1 , wherein the platelet composition comprises plasma.

13. The processing set of claim 1 , wherein the platelet composition comprises a platelet additive solution.

14. The processing set of claim 1 , wherein the platelet composition comprises one or more platelet donations from one or more donors.

15. The processing set of claim 1 , wherein the platelet composition comprises one platelet donation.

16. The processing set of claim 1 , wherein the platelet composition comprises two platelet donations.

17. The processing set of claim 1 , wherein the CAD comprises at least about three grams of adsorbent beads.

18. The processing set of claim 17 , wherein the CAD comprises less than about seven grams of adsorbent beads.

19. The processing set of claim 1 , wherein the CAD comprises at least about seven grams of adsorbent beads.

20. The processing set of claim 2 , wherein the one or more fourth containers are suitable for storing the pathogen-inactivated platelet composition for at least 5 days at room temperature.

21. The processing set of claim 2 , wherein the one or more fourth containers are suitable for storing the pathogen-inactivated platelet composition for up to 7 days at room temperature.

22. The processing set of claim 20 , wherein the pH of the pathogen-inactivated platelet composition after storage is ≥6.2.

23. The processing set of claim 20 , wherein the pH of the pathogen-inactivated platelet composition after storage is ≥6.4.

24. The processing set of claim 1 , wherein the third container is suitable for storing the pathogen-inactivated platelet composition for between about 4 and about 24 hours.

25. The processing set of claim 1 , wherein the pathogen-inactivated platelet composition is one or more pathogen-inactivated platelet units suitable for infusion.

26. The processing set of claim 1 , wherein the pathogen-inactivated platelet composition is two pathogen-inactivated platelet units suitable for infusion.

27. The processing set of claim 1 , wherein the pathogen-inactivated platelet composition is three pathogen-inactivated platelet units suitable for infusion.

28. The processing set of claim 1 , wherein the pathogen-inactivated platelet unit suitable for infusion is a therapeutic dosage unit of pathogen-inactivated platelets.

29. The processing set of claim 21 , wherein the pH of the pathogen-inactivated platelet composition after storage is ≥6.2.

30. The processing set of claim 21 , wherein the pH of the pathogen-inactivated platelet composition after storage is ≥6.4.

31. The processing set of claim 2 , wherein the processing set comprises one fourth container.

32. The processing set of claim 3 , wherein the platelet composition comprises less than about 8.0×10 11 platelets.

33. The processing set of claim 4 , wherein the platelet composition comprises less than about 12.0×10 11 platelets.

34. The processing set of claim 1 , wherein the platelet composition has a volume of about 250 mL to about 650 mL.

35. A processing set for preparing a pathogen-inactivated platelet composition, comprising:

(a) a first container that contains a pathogen inactivation compound (PIC) and is suitable for combining a platelet composition with the PIC, wherein the PIC is a psoralen;

(b) a second container, coupled to the first container, within which the platelet composition in admixture with the PIC can be photochemically inactivated, wherein the platelet composition has a volume of about 250 mL to about 750 ml;

(c) a third container containing a compound adsorption device (CAD), wherein the third container is coupled to the second container such that the photochemically inactivated platelet composition can be transferred from the second container to the third container under sterile conditions, wherein the CAD comprises less than about seven grams of adsorbent beads, and wherein at least one of (i) and (ii) applies:

(i) the volume of the third container is about 1.2 L to about 1.6 L; and

(ii) the surface area of the interior of the third container is about 800 cm 2 to about 1200 cm 2 ; and

(d) two fourth containers, wherein the fourth containers are coupled to the third container such that the photochemically inactivated platelet composition can be transferred from the third container to the fourth containers under sterile conditions to provide the pathogen-inactivated platelet composition, and wherein the fourth containers are suitable for storing the platelet-inactivated platelet composition for at least 5 days at room temperature.

36. The processing set of claim 35 , wherein the platelet composition has a volume of about 250 mL to about 650 mL.

37. A processing set for preparing a pathogen-inactivated platelet composition, comprising:

(a) a first container that contains a pathogen inactivation compound (PIC) and is suitable for combining a platelet composition with the PIC, wherein the PIC is a psoralen;

(b) a second container, coupled to the first container, within which the platelet composition in admixture with the PIC can be photochemically inactivated, wherein the platelet composition has a volume of about 250 mL to about 750 ml;

(c) a third container containing a compound adsorption device (CAD), wherein the third container is coupled to the second container such that the photochemically inactivated platelet composition can be transferred from the second container to the third container under sterile conditions, wherein the CAD comprises at least about seven grams of adsorbent beads, and wherein at least one of (i) and (ii) applies:

(i) the volume of the third container is about 1.2 L to about 1.6 L; and

(ii) the surface area of the interior of the third container is about 800 cm 2 to about 1200 cm 2 ; and

(d) three fourth containers, wherein the fourth containers are coupled to the third container such that the photochemically inactivated platelet composition can be transferred from the third container to the fourth containers under sterile conditions to provide the pathogen-inactivated platelet composition, and wherein the fourth containers are suitable for storing the platelet-inactivated platelet composition for at least 5 days at room temperature.

38. The processing set of claim 37 , wherein the platelet composition has a volume of about 250 mL to about 650 mL.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded May 20, 2026
From: MIDCAP FUNDING IV TRUST
To: CERUS CORPORATION
Reel/Frame 075583/0598 →
RELEASE OF SECURITY INTEREST Recorded May 20, 2026
From: MIDCAP FINANCIAL TRUST
To: CERUS CORPORATION
Reel/Frame 075610/0621 →
AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT (REVOLVING LOAN) Recorded Aug 29, 2025
From: CERUS CORPORATION
To: MIDCAP FUNDING IV TRUST
Reel/Frame 072727/0854 →
AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT (TERM LOAN) Recorded Aug 29, 2025
From: CERUS CORPORATION
To: MIDCAP FINANCIAL TRUST
Reel/Frame 072727/0928 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2024
From: DAVID, TOVO; DONNELLY, BETSY; ERICKSON, ANNA; MUFTI, NAHEED
To: CERUS CORPORATION
Reel/Frame 067051/0799 →
Continuity (4)
Division 15910836 · Mar 2, 2018
Provisional Application 62622127 · Jan 25, 2018
Provisional Application 62467021 · Mar 3, 2017
Related Publication 20220105250A1 · Apr 7, 2022